These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 8912134

  • 1. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha.
    Hirashima N, Mizokami M, Orito E, Koide T, Itazu I, Kumada K, Sakakibara K, Kano H, Lau JY.
    J Gastroenterol Hepatol; 1996 Oct; 11(10):955-8. PubMed ID: 8912134
    [Abstract] [Full Text] [Related]

  • 2. Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy.
    Inoue M, Ohhira M, Ohtake T, Matsumoto A, Kawashima T, Fujimoto Y, Hasebe C, Ono M, Kohgo Y.
    Hepatogastroenterology; 1999 Oct; 46(28):2554-60. PubMed ID: 10522040
    [Abstract] [Full Text] [Related]

  • 3. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K, Sata M, Uchimura Y, Suzuki H, Tanikawa K.
    Oncol Rep; 1998 Oct; 5(1):205-8. PubMed ID: 9458323
    [Abstract] [Full Text] [Related]

  • 4. A patient with hepatitis C-related cirrhosis and hepatocellular carcinoma who was cured with an orthotopic liver transplantation and interferon therapy.
    Shibata M, Yanaga K, Morizane T, Yanagawa T, Hirakawa M, Ueno Y, Esquivel CO, Mitamura K.
    J Gastroenterol; 2003 Oct; 38(6):598-602. PubMed ID: 12858850
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H.
    J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
    [Abstract] [Full Text] [Related]

  • 8. [Viral hepatitis C].
    Zeuzem S, Roth WK, Herrmann G.
    Z Gastroenterol; 1995 Feb; 33(2):117-32. PubMed ID: 7536996
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Clinical significance of interferon therapy in treatments for hepatitis C virus-related hepatocellular carcinoma].
    Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Takemura S, Shiomi S, Kinoshita H.
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):1975-9. PubMed ID: 11791377
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
    Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K.
    Scand J Gastroenterol; 2008 Dec; 43(7):849-56. PubMed ID: 18584524
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
    Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL.
    Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
    [Abstract] [Full Text] [Related]

  • 15. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.
    Tamori A, Nishiguchi S, Shiomi S, Hayashi T, Kobayashi S, Habu D, Takeda T, Seki S, Hirohashi K, Tanaka H, Kubo S.
    Am J Gastroenterol; 2005 Aug; 100(8):1748-53. PubMed ID: 16086711
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term follow-up study of sustained biochemical responders with interferon therapy.
    Shindo M, Hamada K, Oda Y, Okuno T.
    Hepatology; 2001 May; 33(5):1299-302. PubMed ID: 11343259
    [Abstract] [Full Text] [Related]

  • 18. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V, Córdoba J, Berenguer M, Prieto M, Lainez B, Argüello L, Valverde J, Pascual S, Gobernado M, Berenguer J.
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [Abstract] [Full Text] [Related]

  • 19. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K, Fujiyama S, Ohkawa S, Miyakawa K, Tamai S, Hirokawa S, Masaki T, Tanaka K.
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [Abstract] [Full Text] [Related]

  • 20. Therapy of hepatitis C: patients with cirrhosis.
    Schalm SW, Fattovich G, Brouwer JT.
    Hepatology; 1997 Sep; 26(3 Suppl 1):128S-132S. PubMed ID: 9305677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.